Piper Sandler
Experts cautioned, however, that firms will need a broader portfolio than just COVID-19 testing for sustainability in the public markets.
Progenity Raises $40M in Private Placement
The firm said it will use the funds to support its operations, to invest in its molecular testing research and development program, and for working capital.
Investment Banks Initiate Coverage of Talis Biomedical With Bullish Outlooks
Talis, which went public last month, develops point-of-care infectious disease tests based on its flagship Talis One sample-to-answer platform.
Progenity Enters $25M Private Placement
The company will issue units representing an aggregate of shares of common stock and warrants to purchase stock shares at an aggregate purchase price of $5.72.
Investment Banks Initiate Coverage of Ortho Clinical Diagnostics With Bullish Ratings
Piper Sandler analyst Steven Mah noted that Ortho's installed base of more than 20,000 instruments provide it with 93 percent recurring revenue.
Dec 22, 2020